{"disease":{"id":"low-grade-glioma-lgg","name":"low grade glioma lgg"},"drugs":{"marketed":[{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."},{"drug_id":"tovorafenib","indication_name":"relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ojemda","generic_name":"TOVORAFENIB","company_name":"Day One Biopharms","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04201457","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}